Therefore, we examined the effects of representative DNA‐damaging agents (Cisplatin, Doxorubicin, Etoposide, and Carboplatin) and a CDK4/6i (Palbociclib, Abemaciclib) on the senescence of CDK4/6i‐sensitive breast cancer cells. Here, CDK4 is linked to breast carcinoma.